Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics

Vanda Pharmaceuticals Inc. (VNDA)

Today's Latest Price: $11.67 USD

0.21 (-1.77%)

Updated Aug 14 12:00am

Add VNDA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

VNDA Stock Summary

  • VNDA's current price/earnings ratio is 5.6, which is higher than merely 5.87% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for Vanda Pharmaceuticals Inc is higher than it is for about just 8.62% of US stocks.
  • VNDA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 10.71% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vanda Pharmaceuticals Inc are ICAD, AMSC, SSYS, DDD, and APDN.
  • Visit VNDA's SEC page to see the company's official filings. To visit the company's web site, go to
VNDA Daily Price Range
VNDA 52-Week Price Range

VNDA Stock Price Chart Technical Analysis Charts

VNDA Price/Volume Stats

Current price $11.67 52-week high $17.85
Prev. close $11.88 52-week low $7.12
Day low $11.50 Volume 331,500
Day high $11.92 Avg. volume 693,480
50-day MA $11.29 Dividend yield N/A
200-day MA $12.65 Market Cap 637.78M

Vanda Pharmaceuticals Inc. (VNDA) Company Bio

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.

VNDA Latest News Stream

Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream

Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about Vanda Pharmaceuticals Inc that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.

Yahoo | July 29, 2020

Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 22, 2020

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. If you suffered a loss a

Business Wire | July 21, 2020

FDA Grants Extra Access to Vanda's Tradipitant to a Patient

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

Yahoo | July 14, 2020

The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) * Altimmune Inc (NASDAQ: ALT) (announced positive preclinical data for its intranasal vaccine candidate AdCOVID) * argenx SE - ADR (NASDAQ: ARGX) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (reacted to preliminary second-quarter results) * Beigene Ltd (NASDAQ: BGNE) - announced $421 million in additional investment by Amgen, Inc. (NASDAQ: AMGN) in a $2.1-billion direct offering by the Chinese biotech * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Catalent Inc (NYSE: CTLT) * DexCom, Inc. (NASDAQ: DXCM) * Equillium Inc (...

Yahoo | July 14, 2020

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo 1.21%
3-mo 1.83%
6-mo N/A
1-year -23.17%
3-year -28.40%
5-year -5.12%
YTD -28.88%
2019 -37.20%
2018 71.91%
2017 -4.70%
2016 71.32%
2015 -34.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8315 seconds.